EA201591793A1 - Лактамные соединения в качестве селективных агонистов ep4-рецепторов для применения при лечении опосредованных ep4 заболеваний и состояний - Google Patents

Лактамные соединения в качестве селективных агонистов ep4-рецепторов для применения при лечении опосредованных ep4 заболеваний и состояний

Info

Publication number
EA201591793A1
EA201591793A1 EA201591793A EA201591793A EA201591793A1 EA 201591793 A1 EA201591793 A1 EA 201591793A1 EA 201591793 A EA201591793 A EA 201591793A EA 201591793 A EA201591793 A EA 201591793A EA 201591793 A1 EA201591793 A1 EA 201591793A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
receptors
states
mediated diseases
selective agonists
Prior art date
Application number
EA201591793A
Other languages
English (en)
Inventor
Стефен Дуглас Баррет
Джозеф Майкл Коломбо
Брэдли Дэвид Джермейн
Грегори Уилльям Эндрес
Андрий Корнилов
Джеймс Бернард Крамер
Адам Узибло
Фред Лоренс Циске
Кирк М. Макси
Джеймс Пол О'Малли
Томас Аллен Оуэн
Original Assignee
Кайман Кемикал Компани, Инк.
МАЙОМЕТРИКС ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кайман Кемикал Компани, Инк., МАЙОМЕТРИКС ЭлЭлСи filed Critical Кайман Кемикал Компани, Инк.
Publication of EA201591793A1 publication Critical patent/EA201591793A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)
  • Pyrrole Compounds (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

В заявке раскрыты соединения формулы (I)где L, L, L, L, R, R, R, Rи s определены в описании. Соединения формулы (I) представляют собой агонисты ЕР4, пригодные при лечении глаукомы, остеопороза, перелома кости, потери периодонтальной костной ткани, ортопедической имплантации, алопеции, нейропатической боли и сопутствующих нарушений. Также описаны фармацевтические композиции и способы лечения состояний и нарушений.
EA201591793A 2013-03-15 2014-03-14 Лактамные соединения в качестве селективных агонистов ep4-рецепторов для применения при лечении опосредованных ep4 заболеваний и состояний EA201591793A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361793736P 2013-03-15 2013-03-15
PCT/US2014/029057 WO2014144584A2 (en) 2013-03-15 2014-03-14 Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions

Publications (1)

Publication Number Publication Date
EA201591793A1 true EA201591793A1 (ru) 2016-01-29

Family

ID=50897877

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591793A EA201591793A1 (ru) 2013-03-15 2014-03-14 Лактамные соединения в качестве селективных агонистов ep4-рецепторов для применения при лечении опосредованных ep4 заболеваний и состояний

Country Status (17)

Country Link
US (1) US9688627B2 (ru)
EP (2) EP2989098B1 (ru)
JP (2) JP6317807B2 (ru)
KR (1) KR20150130326A (ru)
CN (1) CN105143217A (ru)
AU (1) AU2014228973B2 (ru)
BR (1) BR112015023080A2 (ru)
CA (1) CA2906134A1 (ru)
DK (1) DK2989098T3 (ru)
EA (1) EA201591793A1 (ru)
ES (1) ES2635635T3 (ru)
HK (1) HK1222170A1 (ru)
IL (2) IL240988A (ru)
PH (1) PH12015502165A1 (ru)
PT (1) PT2989098T (ru)
SG (1) SG11201507470WA (ru)
WO (1) WO2014144584A2 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2874620B1 (en) 2012-07-19 2016-10-12 Cayman Chemical Company, Incorporated Difluorolactam compositions for ep4-mediated osteo related diseases and conditions
WO2015009991A2 (en) 2013-07-19 2015-01-22 Cayman Chemical Company, Inc. Methods, systems, and compositions for promoting bone growth
CN107365329B (zh) * 2016-05-12 2019-02-01 华东师范大学 一种3-甲基-2-氧代-5-庚炔基磷酸二甲酯的制备方法
PL3733665T3 (pl) 2017-12-25 2023-02-06 Asahi Kasei Pharma Corporation Związki zawierające ugrupowanie 2-okso-1,3,4-tiadiazynan-3-ylowe mające aktywność agonisty receptora EP4
AU2020256166A1 (en) 2019-04-02 2021-10-14 Aligos Therapeutics, Inc. Compounds targeting PRMT5

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3975399A (en) 1974-08-06 1976-08-17 E. I. Du Pont De Nemours And Company 1,5-Disubstituted-2-pyrrolidinones, -3-pyrrolin-2-ones, and -4-pyrrolin-2-ones
DE2517771A1 (de) 1975-04-18 1976-10-28 Schering Ag Neue prostaglandin-acetylen-analoga und verfahren zu ihrer herstellung
CA1085859A (en) 1975-06-27 1980-09-16 Wilhelm Bartmann Pyrrolidones and process for their manufacture
DE2528664A1 (de) 1975-06-27 1977-01-13 Hoechst Ag Pyrrolidone und verfahren zu ihrer herstellung
DE2619638A1 (de) * 1976-05-04 1977-11-17 Hoechst Ag Pyrrolidone und verfahren zu ihrer herstellung
US4268522A (en) 1976-06-14 1981-05-19 Pfizer Inc. 13,14-Dihydro-15-alkenyl- and 13,14-dihydro-15-alkynyl prostaglandins and analogs thereof
US4320136A (en) 1980-08-11 1982-03-16 E. I. Du Pont De Nemours And Company 8-Aza-16,16-difluoroprostanoids
US6043275A (en) 1998-04-16 2000-03-28 Ono Pharmaceutical Co., Ltd. 3,7-dithiaprostanoic acid derivative
US6894175B1 (en) 1999-08-04 2005-05-17 The Procter & Gamble Company 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
TWI247606B (en) 1999-11-24 2006-01-21 Ono Pharmaceutical Co Treating agent for osteopenic diseases
CN1413190A (zh) * 1999-12-22 2003-04-23 辉瑞产品公司 治疗骨质疏松的ep4受体选择性激动剂
US20010056060A1 (en) 2000-02-07 2001-12-27 Cameron Kimberly O. Treatment of osteoporsis with EP2/EP4 receptor selective agonists
WO2002024647A1 (fr) 2000-09-21 2002-03-28 Ono Pharmaceutical Co., Ltd. Agonistes du recepteur de l'ep4 comprenant comme principe actif des derives de la 8-azaprostaglandine
IL155368A0 (en) 2000-11-27 2003-11-23 Pfizer Prod Inc Ep4 receptor selective agonists in the treatment of osteoporosis
ES2254726T3 (es) 2001-07-16 2006-06-16 F. Hoffmann-La Roche Ag Analogos de prostaglandina como agonistas receptores de ep4.
EP1408961B1 (en) 2001-07-16 2007-07-11 F. Hoffmann-La Roche Ag 2 pyrrolidone derivatives as prostanoid agonists
HU230421B1 (hu) 2001-07-23 2016-05-30 Ono Pharmaceutical Co., Ltd Csonttömegveszteséggel kapcsolatos betegségek kezelésére adható, EP4 agonistát tartalmazó gyógyászati készítmények és hatóanyagként alkalmazható vegyületek
DE60226051T2 (de) 2001-10-23 2009-05-20 Laboratoires Serono S.A., Coinsins Pyrazolidinon-verbindungen als liganden des ep2 und/oder ep4 prostaglandin-rezeptoren
EP1461026A2 (en) 2001-12-03 2004-09-29 Merck & Co., Inc. Method for treating ocular hypertension
US20040204590A1 (en) 2001-12-03 2004-10-14 Ogidigben Miller J. Ep4 receptor agonist, compositions and methods thereof
EP1481976B1 (en) 2002-03-05 2012-11-07 Ono Pharmaceutical Co., Ltd. 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient
EP1487437B1 (en) 2002-03-18 2006-08-16 Pfizer Products Inc. Use of selective ep4 receptor agonists for the treatment of diseases
AU2003209571A1 (en) 2002-03-18 2003-09-29 Pfizer Products Inc. Use of selective ep4 receptor agonists for the treatment of liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension
US6573294B1 (en) 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure
EP1556347A4 (en) * 2002-06-10 2006-08-09 Applied Research Systems GAMMA LACTAME AS PROSTAGLAND INAGONISTS AND THEIR USE
US20060167081A1 (en) 2002-10-25 2006-07-27 Xavier Billot Ep4 receptor agonists
WO2004065365A1 (ja) 2003-01-21 2004-08-05 Ono Pharmaceutical Co., Ltd. ８−アザプロスタグランジン誘導体およびその医薬用途
US7276531B2 (en) * 2003-03-03 2007-10-02 Applied Research Systems Ars Holding N.V. G-lactam derivatives as prostaglandin agonists
US7169807B2 (en) 2004-04-09 2007-01-30 Allergan, Inc. 10-Hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists
WO2006016689A1 (ja) 2004-08-10 2006-02-16 Ono Pharmaceutical Co., Ltd. Ｅｐ４アゴニストを含有してなる下部尿路系疾患の予防および／または治療剤
JPWO2006016695A1 (ja) 2004-08-10 2008-05-01 小野薬品工業株式会社 Ｅｐ４アゴニストを含有してなる高カリウム血症の予防および／または治療剤
CA2610692C (en) * 2005-06-03 2014-11-25 Ono Pharmaceutical Co., Ltd. Ep2 agonists which may have an ep3 agonistic effect for regeneration and/or protection of nerves
US20070232660A1 (en) 2006-04-04 2007-10-04 Allergan, Inc. Therapeutic and delivery methods of prostaglandin ep4 agonists
WO2008136519A1 (ja) 2007-05-08 2008-11-13 National University Corporation, Hamamatsu University School Of Medicine Ｅｐ４アゴニストを含有してなる細胞傷害性ｔ細胞の活性化剤
JP5410438B2 (ja) 2007-10-23 2014-02-05 アラーガン インコーポレイテッド 治療用置換ラクタム類
WO2011003058A1 (en) * 2009-07-03 2011-01-06 Concert Pharmaceuticals, Inc. Prostacyclin derivatives
US9242970B2 (en) 2010-11-10 2016-01-26 Actelion Pharmaceuticals Ltd. Lactam derivatives useful as orexin receptor antagonists
US20120283293A1 (en) 2011-05-06 2012-11-08 The Board Of Trustees Of The Leland Stanford Junior University Methods of neuroprotection involving Prostaglandin E2 EP4 (PGE2 EP4) receptor activation
AU2012290987B2 (en) 2011-08-02 2017-04-20 Ono Pharmaceutical Co., Ltd. Left ventricular diastolic function improving agent
EP2874620B1 (en) 2012-07-19 2016-10-12 Cayman Chemical Company, Incorporated Difluorolactam compositions for ep4-mediated osteo related diseases and conditions

Also Published As

Publication number Publication date
IL250077A0 (en) 2017-03-30
PT2989098T (pt) 2017-08-16
JP6317807B2 (ja) 2018-04-25
EP2989098A2 (en) 2016-03-02
JP2017186356A (ja) 2017-10-12
SG11201507470WA (en) 2015-10-29
EP3235817B1 (en) 2018-12-12
KR20150130326A (ko) 2015-11-23
EP2989098B1 (en) 2017-05-10
EP3235817A1 (en) 2017-10-25
BR112015023080A2 (pt) 2017-07-18
AU2014228973A1 (en) 2015-09-17
US9688627B2 (en) 2017-06-27
ES2635635T3 (es) 2017-10-04
HK1222170A1 (zh) 2017-06-23
IL240988A0 (en) 2015-11-30
WO2014144584A3 (en) 2014-11-20
JP6352497B2 (ja) 2018-07-04
DK2989098T3 (en) 2017-08-28
US20160060216A1 (en) 2016-03-03
PH12015502165A1 (en) 2016-01-25
WO2014144584A2 (en) 2014-09-18
CN105143217A (zh) 2015-12-09
CA2906134A1 (en) 2014-09-18
IL240988A (en) 2017-05-29
AU2014228973B2 (en) 2018-11-08
JP2016516050A (ja) 2016-06-02

Similar Documents

Publication Publication Date Title
PH12016500105A1 (en) Sulfonamides as modulators of sodium channels
EA201992878A1 (ru) Соединения для лечения болезни хантингтона
EA201390772A1 (ru) Новые соли и полиморфные формы афатиниба
PH12015501740A1 (en) Sodium channel modulators for the treatment of pain
EA201300471A1 (ru) Замещенные 6-аминоникотинамиды в качестве модуляторов kcnq2/3
PH12015502854A1 (en) Methods, systems, and compositions for promoting bone growth
MX359882B (es) Amidas como moduladores de canales de sodio.
EA201100654A1 (ru) Соединения для лечения офтальмологических заболеваний и расстройств
EA201170922A1 (ru) Производные сульфонамида
EA200970747A1 (ru) Антагонисты активина-actriia и применение для стимуляции роста кости у больных раком
MX2015009592A (es) Quinolina y quinazolina amidas como moduladores de canales de sodio.
EA201100750A1 (ru) Замещенные диоксопиперидинилфталимидные производные
EA200970913A1 (ru) 2-пиридинкарбоксамидные производные в качестве модуляторов натриевых каналов
EA201390682A1 (ru) Спирооксиндольные антагонисты mdm2
EA200870569A1 (ru) Соединения и способы модуляции fxr
EA201071045A1 (ru) Соединения оксадиазоантрацена для лечения диабета
WO2015157559A3 (en) 10',11'-modified saxitoxins useful for the treatment of pain
EA201071038A1 (ru) Производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40
MX2016002881A (es) Moduladores del canal de sodio para el tratamiento de dolor y diabetes.
EA201591793A1 (ru) Лактамные соединения в качестве селективных агонистов ep4-рецепторов для применения при лечении опосредованных ep4 заболеваний и состояний
EA201891377A1 (ru) ПРИМЕНЕНИЕ МОДУЛЯТОРОВ КАНАЛОВ Kv3.1/Kv3.2/Kv3.3 ДЛЯ ЛЕЧЕНИЯ БОЛИ
EA201692049A1 (ru) Гетероарилзамещенные гетероциклилсульфоны
EA201591541A1 (ru) Ингибиторы бета-секретазы 1 (bace 1)
EA201300988A1 (ru) Мягкая фармацевтическая композиция на водной основе, содержащая тапентадол
CY1116234T1 (el) Υποκατεστημενα 2-οξυ-κινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3